Originally published March 3.
Roche's announcement this week that it is halting a Phase III trial of its investigational non-small cell lung cancer drug onartuzumab in combination with Tarceva (erlotinib) in previously treated patients with MET-positive tumors may have implications for other trials the company is running that are exploring a similar molecularly targeted treatment strategy in lung cancer patients.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
